Biolidics shares sink 22% after calling off US sales of Covid-19 test kits
Add BT as a preferred sourceSingapore
BIOLIDICS shares sank 22 per cent on Monday after the Catalist-listed firm announced on Sunday that it had mutually agreed with Aytu BioScience to terminate a distribution agreement for its Covid-19 antibody test kits in the US, amid increased competition for such kits.
Shares of Biolidics, which ended Friday at 41 Singapore cents, plunged to 29.5 cents as at 8.58am on Monday. The stock recovered to 35 cents as at 9.26am, before closing at 32 cents, down nine cents.
TRENDING NOW
Electricity tariff to rise significantly from July despite Iran deal: EMA
What’s wrong with Orchard Road? Experts weigh in on the street’s cachet and its future
‘I felt like dying’: Thai Singha beer scion speaks up after disclosure of alleged sexual abuse
Onitsuka Tiger pivots from Asics stripes to tap luxury market
